BETHESDA, Md., Feb. 24, 2011 /PRNewswire/ -- BrainScope Company, Inc. today announced that Peter JD Andrews M.D., MB.Ch.B., FRCA has joined its Medical Advisory Board. He holds the distinguished title of Professor of Anaesthetics & Critical Care at the University of Edinburgh, Scotland, United Kingdom. This appointment coincides with BrainScope's recent announcement that it is entering the U.K. market with its "B-Ahead U.K. Trial", a multi-center, observational clinical study utilizing its technology in development to aid in the assessment of traumatic brain injury (TBI) and its milder forms (commonly referred to as "concussion") in emergency departments in the U.K.
"Professor Andrews is one of the most preeminent traumatic brain injury thought leaders in the world today," said BrainScope Chief Executive Officer Michael Singer. "His extensive background and combined focus on brain injury and critical care make him a perfect addition to our Medical Advisory Board. We are honored that he has joined us and look forward to learning from him, particularly with our continuing focus on the United Kingdom."
In addition to his professorship at the University of Edinburgh, Professor Andrews is currently Consultant in Anaesthesia and Intensive Care at Western General Hospital in Edinburgh, Scotland. He is a member of the European Society of Intensive Care Medicine, and previously elected section Chairman of Neurological Intensive Care on two occasions and a member of the Medical Research Council (UK) College of Experts. He is currently involved in several research grants, including the Eurotherm3235Trial, an international, multi-center, randomized controlled trial that examines the effects of hypothermia as a treatment for severe traumatic brain injury, where he serves as chief investigator. Professor Andrews is editor in chief for The Open Critical Care Medicine Journal and has been associate editor of Intensive Care Medicine. He has authored and co-authored 145 peer-reviewed journal articles and 28 books, many of which focus on head injury. In the past year, Professor Andrews has participated in such illustrious events as the International Critical Care Symposium in Chennai, India, where he was chairman of the opening ceremony, and the International Symposium on Intensive Care and Emergency Medicine.
"I am very pleased and honored to join this very fine group of physicians that comprise BrainScope's Medical Advisory Board," said Professor Andrews. "Traumatic brain injury is a major cause of death and disability throughout the world. It is exciting to have such promising technology come to the United Kingdom, and I look forward to working with BrainScope's other clinical advisors and management to help develop this technology to make it accessible to the millions of people who can benefit from it each year."
BrainScope's Medical Advisory Board is comprised of prominent medical experts with expertise in multiple fields applicable to BrainScope's focus on developing products for assessment of TBI and concussion, including emergency medicine, military medicine, sports medicine, pediatrics, neurology and neurosurgery. In addition to Professor Andrews, the Medical Advisory Board consists of the following members:
Backed by Revolution LLC (created by AOL co-founder Steve Case), Alafi Capital, Brain Trust Accelerator Fund, Draper Fisher Jurvetson, Portage Ventures and ZG Ventures, BrainScope is a medical neurotechnology company that is developing a new generation of hand-held, simple-to-use, non-invasive instruments designed to aid medical professionals in rapidly, accurately, and objectively assessing brain function at the initial point of care. BrainScope devices in development are based on a proprietary technology platform, which integrates databases of brainwave recordings with advanced developments in digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors. BrainScope's initial focus is on traumatic brain injury (TBI) and its milder forms known as concussion. BrainScope's unique device is being developed to meet a long-standing clinical need for improved early identification, staging and triage for head-injured patients. BrainScope devices under development for assessment of traumatically-induced head injury and concussions are for investigational use only and have not been submitted for FDA marketing review. For more information please visit www.brainscope.com.
|SOURCE BrainScope Company, Inc.|
Copyright©2010 PR Newswire.
All rights reserved